Evolus (EOLS) Misses Q1 EPS by 7c, Tops on Revenue; Offers FY24 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. LDOS
8. AXP
9. HUM
10. CSCO

Go back to Evolus (EOLS) Misses Q1 EPS by 7c, Tops on Revenue; Offers FY24 Revenue Guidance

Evolus Reports First Quarter 2024 Results and Provides Business Update

May 7, 2024 4:05 PM EDT

Q1 2024 Net Revenue of $59.3 Million, Up 42% from Q1 2023 Non-GAAP Loss from Operations of $0.9 Million, on Track to Non-GAAP Profitability1 in Q4 2024 and Full Year 2025 U.S. Clinical Trials Completed for Evolysse® Lift and Smooth fillers, FDA Submission Expected within Next 90 Days Reaffirms Full-Year 2024 Net Revenue Guidance of $255 Million to $265 Million, Representing a 31% Growth Rate at the Top End Remains on Track to Achieve Projected Total Net Revenue Goal of At Least $700 Million by 2028

NEWPORT BEACH, Calif.--(BUSINESS... More